The 17-patient Phase 1 analysis linked BBT001 to rapid itch relief, early EASI improvement, sustained biomarker suppression, and …
The 17-patient Phase 1 analysis linked BBT001 to rapid itch relief, early EASI improvement, sustained biomarker suppression, and …
The Phase 1/2 program reached projected target exposure without identifying a maximum tolerated dose, allowing monotherapy expansion while …
Fresh capital will push DF-003 through Phase 3 for the rare inflammatory disorder ROSAH syndrome and DF-006 through …
New PMN310 data presented in London show measurable drops in cerebrospinal fluid amyloid-beta oligomers at three and 29 …
BL1107 failed to replicate visual function improvements seen in an earlier, smaller study, prompting the company to redirect …
Optimized dosing regimen achieved steady-state drug levels nine weeks earlier than in the trial’s first phase, as the …
New blood biomarker data from Eli Lilly, Roche and Alamar Biosciences headline a London conference where non-amyloid mechanisms …
Genmab and AbbVie’s bispecific antibody met its primary endpoint in a head-to-head comparison, positioning the CD3xCD20 therapy for …
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as …
The bispecific antibody paired with lenalidomide showed a statistically significant improvement over standard care in patients with relapsed …
Already a subscriber? Log in